- Uppsala research facility upgrade will broaden research capabilities
- New formulations of Cantrixil will be developed at these new facilities
Solna, Sweden, 17 March 2022 – Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, is pleased to announce the planned upgrade of its Research and Development laboratory facility for formulations intended to treat cancers.
The laboratory facilities, in Uppsala, Sweden, are being upgraded to provide greater capacity to handle these formulations which include new formulations of Cantrixil and formulations using Oasmia’s proprietary drug delivery platform.
Oasmia acquired the global development and commercialization rights for Cantrixil from Kazia Therapeutics, an Australian oncology-focused biotechnology company in March 2021. Following the publication of positive Phase I results, Oasmia is now preparing for the initiation of a Phase II trial of an intraperitoneal formulation of Cantrixil in advanced ovarian cancer. Oasmia will, among other things, be developing a preclinical intravenous formulation of Cantrixil which will be developed at the new facility in Uppsala.
Kai Wilkinson PhD., Chief Technical Officer of Oasmia, commented “With this new laboratory facility, we will be expanding our capabilities to provide novel developments and formulations. Not only will we be able to formulate new compounds for further clinical testing, but we will also be able to handle more advanced synthesis work, if required.”
For More Information:
Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
Consilium Strategic Communications (For Oasmia)
Jonathan Birt, Ashley Tapp
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.